PharmaCyte Biotech, Inc. (PMCB) › Shareholders' EquityPharmaCyte Biotech, Inc. (PMCB) — Shareholders' EquityAnnual figures by period end, from SEC filings.2010-04-30: -$2.45M2011-04-30: -$2.73M2012-04-30: -$2.28M2013-04-30: -$1.50M2014-04-30: $8.94M2015-04-30: $7.78M2016-04-30: $6.52M2017-04-30: $8.09M2018-04-30: $5.77M2019-04-30: $5.04M2020-04-30: $5.09M2021-04-30: $6.68M2022-04-30: $89.92M2023-04-30: $72.69M2024-04-30: $27.65M2025-04-30: $51.89M2026-04-30: $33.29M$33.29M2010-04-30Shareholders' Equity (USD)2026-04-30Period endedShareholders' EquityChange YoYSource filing2026-04-30$33.29M-35.8%2026-07-29Balance as of period end2025-04-30$51.89M+87.7%2026-07-29Balance as of period end2024-04-30$27.65M-62.0%2026-07-29Balance as of period end2023-04-30$72.69M-19.2%2025-08-11Balance as of period end2022-04-30$89.92M+1246.2%2024-08-13Balance as of period end2021-04-30$6.68M+31.3%2023-07-31Balance as of period end2020-04-30$5.09M+1.0%2022-07-28Balance as of period end2019-04-30$5.04M-12.6%2021-08-10Balance as of period end2018-04-30$5.77M-28.7%2020-08-13Balance as of period end2017-04-30$8.09M+24.0%2019-08-13Balance as of period end2016-04-30$6.52M-16.1%2018-07-20Balance as of period end2015-04-30$7.78M-13.0%2017-07-27Balance as of period end2014-04-30$8.94M—2016-07-29Balance as of period end2013-04-30-$1.50M—2016-07-29Balance as of period end2012-04-30-$2.28M—2016-01-19Balance as of period end2011-04-30-$2.73M—2013-07-29Balance as of period end2010-04-30-$2.45M—2012-08-14Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)